The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects

Inclusion Criteria: * Male or female, overall healthy subjects; * Between 18 and 45 years of age, inclusive, similar ages; * Body weight should be≥50 kg; Body Mass Index (BMI) is between 19 and 25 kg/m2, inclusive, similar body weights; * Able to comprehend and sign the ICF voluntarily prior to initiate the study; * Able to communicate well with the investigator and complete the study according to the protocol. Exclusion Criteria: * Pregnant or nursing female, or plan for pregnancy within 6 months; * Female with positive urine pregnancy test results; * Positive test results for HBsAg, anti-HCV Ab, anti-HIV Ab or syphilis; * Have taken any drug inhibiting gastric acid secretion within 1 month prior to study drug administration, such as: H2 receptor antagonists (eg: Cimetidine, Ranitidine, Famotidine, Nizatidine and Roxatidine); Proton pump inhibitors (eg: Omeprazole, Lansoprazole, Rabeprazole, Pantoprazole and Esomeprazole); cholinoceptor blocking drugs (eg: Atropine and Pirenzepine); * History of immune system disease (such as thymus disease); * Have undergone major surgery within 6 months before enrollment; * History of tumor; * Drink frequently within 6 months prior to study drug administration, namely alcohol consumption are more than 20 grams per day; * Smokers, who smoke more than 1 cigarettes/day within 3 months before the study; * Participated in any clinical trial within 3 months prior to the study; * Cannot be tolerant to oral drugs.